Masimo Corporation (NASDAQ:MASI) issued its quarterly earnings data on Tuesday. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.53 by $0.17, Briefing.com reports. The firm had revenue of $193.69 million during the quarter, compared to analysts’ expectations of $189.01 million. Masimo Corporation had a net margin of 45.90% and a return on equity of 23.45%. The business’s revenue was up 15.6% on a year-over-year basis. During the same period last year, the company earned $0.52 earnings per share.
Masimo Corporation (NASDAQ:MASI) traded up 1.06% on Tuesday, reaching $87.76. 442,952 shares of the company traded hands. The stock’s 50 day moving average price is $86.06 and its 200 day moving average price is $89.33. Masimo Corporation has a one year low of $53.78 and a one year high of $104.71. The company has a market capitalization of $4.56 billion, a PE ratio of 14.38 and a beta of 0.82.
In related news, Director Sanford Fitch sold 11,000 shares of the stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $87.25, for a total transaction of $959,750.00. Following the sale, the director now directly owns 72,249 shares of the company’s stock, valued at approximately $6,303,725.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 16.60% of the company’s stock.
A number of brokerages have recently issued reports on MASI. Zacks Investment Research cut shares of Masimo Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. BidaskClub cut shares of Masimo Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Roth Capital boosted their price target on shares of Masimo Corporation from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, July 19th. BTIG Research upgraded shares of Masimo Corporation from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a report on Monday, August 14th. Finally, Stifel Nicolaus assumed coverage on shares of Masimo Corporation in a report on Monday, July 10th. They set a “buy” rating and a $105.00 price target on the stock. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company’s stock. Masimo Corporation presently has a consensus rating of “Hold” and a consensus price target of $97.00.
About Masimo Corporation
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
What are top analysts saying about Masimo Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Masimo Corporation and related companies.